US2021032313A1PendingUtilityA1

Klk5 inhibitory peptide

67
Assignee: DAIICHI SANKYO CO LTDPriority: Nov 7, 2018Filed: Oct 6, 2020Published: Feb 4, 2021
Est. expiryNov 7, 2038(~12.3 yrs left)· nominal 20-yr term from priority
Inventors:Daisuke NishimiyaHidenori YanoHidenori TakahashiShinji YamaguchiShiho Ofuchi
C07K 14/8135A61K 38/57G01N 2500/00G01N 33/68C07K 2319/30C07K 14/811A61P 35/00A61P 17/16A61P 17/06A61P 11/06A61K 47/68A61K 47/64A61K 38/00G01N 33/53G01N 33/50G01N 33/15C12Q 1/37C12N 15/63C12N 9/64C12N 5/10C07K 19/00C07K 16/00C07K 14/81A61P 43/00A61P 37/08A61P 29/00A61P 25/00A61P 17/02A61P 17/00A61P 1/04A61K 48/00A61K 47/65A61K 45/00A61K 38/55A61K 35/12
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided is a novel peptide. The peptide contains the amino acid sequence set forth in SEQ ID NO: 61 and inhibits a protease.

Claims

exact text as granted — not AI-modified
1 . A peptide comprising the amino acid sequence set forth in any one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, and 60. 
     
     
         2 . A composition comprising the peptide according to  claim 1 . 
     
     
         3 . The composition according to  claim 2 , wherein the composition is a pharmaceutical composition. 
     
     
         4 . The composition according to  claim 3 , further comprising an additional pharmaceutical product. 
     
     
         5 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 34. 
     
     
         6 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 36. 
     
     
         7 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 38. 
     
     
         8 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 40. 
     
     
         9 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 42. 
     
     
         10 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 44. 
     
     
         11 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 46. 
     
     
         12 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 48. 
     
     
         13 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 96. 
     
     
         14 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 50. 
     
     
         15 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 52. 
     
     
         16 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 54. 
     
     
         17 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 58. 
     
     
         18 . The peptide of  claim 1  comprising the amino acid sequence set forth in SEQ ID NO: 60. 
     
     
         19 . A peptide comprising the amino acid sequence set forth in SEQ ID NO: 34. 
     
     
         20 . A composition comprising the peptide according to  claim 19 . 
     
     
         21 . The composition according to  claim 20 , wherein the composition is a pharmaceutical composition. 
     
     
         22 . The composition according to  claim 21 , further comprising an additional pharmaceutical product. 
     
     
         23 . A peptide comprising the amino acid sequence set forth in SEQ ID NO: 36. 
     
     
         24 . A composition comprising the peptide according to  claim 23 . 
     
     
         25 . The composition according to  claim 24 , wherein the composition is a pharmaceutical composition. 
     
     
         26 . The composition according to  claim 25 , further comprising an additional pharmaceutical product. 
     
     
         27 . A peptide comprising the amino acid sequence set forth in SEQ ID NO: 38. 
     
     
         28 . A composition comprising the peptide according to  claim 27 . 
     
     
         29 . The composition according to  claim 28 , wherein the composition is a pharmaceutical composition. 
     
     
         30 . The composition according to  claim 29 , further comprising an additional pharmaceutical product.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.